N‐(4‐methoxy‐1,3‐benzothiazol‐2‐yl)‐5‐nitrofuran‐2‐carboxamide | 219619-15-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N‐(4‐methoxy‐1,3‐benzothiazol‐2‐yl)‐5‐nitrofuran‐2‐carboxamide
• 英文别名: 5-nitro-furan-2-carboxylic acid (4-methoxy-benzothiazol-2-yl)-amide；5-nitrofuran-2-carboxylic acid(4-methoxy-benzothiazol-2-yl)-amide；2-Furancarboxamide, N-(4-methoxy-2-benzothiazolyl)-5-nitro-；N-(4-methoxy-1,3-benzothiazol-2-yl)-5-nitrofuran-2-carboxamide
• CAS: 219619-15-5
• 化学式: C₁₃H₉N₃O₅S
• 分子量: 319.298
• InChiKey: ZBDGUDDZLCHJHI-UHFFFAOYSA-N

物化性质

• 密度：
  1.566±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  138
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-硝基-2-糠酸 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 N‐(4‐methoxy‐1,3‐benzothiazol‐2‐yl)‐5‐nitrofuran‐2‐carboxamide
  参考文献：
  名称：

  Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents

  摘要：

  In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofaranylamides. We have discovered a number of nitrofaranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.

  DOI：

  10.1021/jm049972y

文献信息

• Heterocyclic amides with anti-tuberculosis activity
  申请人：Lee E. Richard

  公开号：US20050222408A1

  公开（公告）日：2005-10-06

  Compounds having the general structure: wherein A is selected from the group consisting of oxygen, sulfur, and NR 15 , and R 15 is selected from the group consisting of H, alkyl, aryl, substituted alkyl, and substituted aryl; B,D, and E are each independently selected from the group consisting of CH, nitrogen, sulfur and oxygen; R 1 is selected from the group consisting of nitro, halo, alkyl ester, arylsulfanyl, arylsulfinyl, arylsulfonyl and sulfonic acid; t is an integer from 1 to 3; and X is a substituted amide, and methods of using the novel compounds for treating infections caused by microorganisms, including Mycobacterium tuberculosis.

  具有一般结构的化合物：其中A从氧、硫和NR15组成的群体中选择，R15从H、烷基、芳基、取代烷基和取代芳基组成的群体中选择；B、D和E分别独立地从CH、氮、硫和氧组成的群体中选择；R1从硝基、卤素、烷基酯、芳基硫醚、芳基亚砜、芳基砜基和磺酸中选择；t为1到3的整数；X为取代酰胺，并且使用这些新化合物治疗由微生物引起的感染的方法，包括结核分枝杆菌。
• Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound
  作者：Tatiana A. Giovannucci、Florian A. Salomons、Martin Haraldsson、Lotta H. M. Elfman、Malin Wickström、Patrick Young、Thomas Lundbäck、Jürgen Eirich、Mikael Altun、Rozbeh Jafari、Anna-Lena Gustavsson、John Inge Johnsen、Nico P. Dantuma

  DOI：10.1038/s41419-021-04191-9

  日期：——

  Malignant cells display an increased sensitivity towards drugs that reduce the function of the ubiquitin-proteasome system (UPS), which is the primary proteolytic system for destruction of aberrant proteins. Here, we report on the discovery of the bioactivatable compound CBK77, which causes an irreversible collapse of the UPS, accompanied by a general accumulation of ubiquitylated proteins and caspase-dependent cell death. CBK77 caused accumulation of ubiquitin-dependent, but not ubiquitin-independent, reporter substrates of the UPS, suggesting a selective effect on ubiquitin-dependent proteolysis. In a genome-wide CRISPR interference screen, we identified the redox enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) as a critical mediator of CBK77 activity, and further demonstrated its role as the compound bioactivator. Through affinity-based proteomics, we found that CBK77 covalently interacts with ubiquitin. In vitro experiments showed that CBK77-treated ubiquitin conjugates were less susceptible to disassembly by deubiquitylating enzymes. In vivo efficacy of CBK77 was validated by reduced growth of NQO1-proficient human adenocarcinoma cells in nude mice treated with CBK77. This first-in-class NQO1-activatable UPS inhibitor suggests that it may be possible to exploit the intracellular environment in malignant cells for leveraging the impact of compounds that impair the UPS.

  恶性细胞对降低泛素蛋白酶体系统（UPS）功能的药物表现出增加的敏感性，UPS是异常蛋白质降解的主要蛋白质系统。在这里，我们报告了生物活化化合物CBK77的发现，它导致UPS的不可逆性崩溃，伴随着泛素化蛋白的普遍积累和caspase依赖的细胞死亡。CBK77导致了依赖泛素而非独立于泛素的UPS报告底物的积累，表明对依赖泛素的蛋白质降解具有选择性影响。在全基因组CRISPR干扰筛选中，我们确定了氧化还原酶NAD(P)H：喹啉醌还原酶1（NQO1）作为CBK77活性的关键介导体，并进一步证明了其作为化合物生物活化剂的作用。通过亲和力基础蛋白质组学，我们发现CBK77与泛素发生共价作用。体外实验显示，CBK77处理后的泛素结合物对去泛素化酶的解聚作用较不敏感。在NQO1-proficient人类腺癌细胞中，用CBK77处理的裸鼠显示了CBK77的体内有效性。这种首创的NQO1活化的UPS抑制剂表明，可能可以利用恶性细胞内部环境来增强影响破坏UPS的化合物的作用。

• [EN] HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY<br/>[FR] AMIDES HETEROCYCLIQUES A ACTIVITE ANTI-TUBERCULINIQUE
  申请人：UNIV TENNESSEE RES FOUNDATION

  公开号：WO2005007625A3

  公开（公告）日：2005-12-29
• Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents
  作者：Rajendra P. Tangallapally、Raghunandan Yendapally、Robin E. Lee、Kirk Hevener、Victoria C. Jones、Anne J. M. Lenaerts、Michael R. McNeil、Yuehong Wang、Scott Franzblau、Richard E. Lee

  DOI：10.1021/jm049972y

  日期：2004.10.1

  In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofaranylamides. We have discovered a number of nitrofaranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.